Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Pfizer's transitions from pandemic success to market concerns: analyzing revenue stagnation, investor reactions, and the company's strategic roadmap for growth. The former employee and his friend ...

Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.